The American Society of Clinical Oncology (ASCO), along with nearly 60 other organizations, joined the American Cancer Society Cancer Action Network (ACS CAN) in an advertising campaign urging the Department of Health and Human Services (HHS) and Congress to halt proposed changes to Medicare Part D’s six protected classes.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
In a comment letter to the Centers for Medicare & Medicaid Services (CMS), ASCO urged the agency to ensure that every Medicaid enrollee with cancer can access the high-quality care needed to treat their disease. The comments were submitted in response to a proposed rule on Medicaid and the Children’s Health Insurance Plan (CHIP) Managed Care that aims to streamline the programs’ regulatory requirements, reduce administrative burden, and increase flexibility for state governments.
On January 14, 2019, the Food and Drug Administration approved cabozantinib (CABOMETYX®, Exelixis, Inc.) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
ASCO congratulates Anand Shah, MD, MPH, on being named Senior Medical Advisor for Innovation at the Centers for Medicare & Medicaid Services (CMS). In his new role, Dr. Shah will lead efforts across CMS to advance medical innovation reporting directly to CMS Administrator Seema Verma.
Statement from American Society of Clinical Oncology (ASCO) President Monica M. Bertagnolli, MD, FACS, FASCO, on the American Cancer Society Cancer Facts and Figures 2019 Report
A new global resource that includes data on thousands of inherited variants in the BRCA1 and BRCA2 genes will help inform the understanding of cancer risk. Wendy Rubinstein, MD, PhD, FACP, FACMG, and Deputy Medical Director of CancerLinQ, LLC, a wholly owned nonprofit subsidiary of ASCO, served as a co-author of the new paper published this week in PLOS Genetics detailing the development of the new resource, BRCA Exchange.
Reimbursement cuts for certain oncology specialties. Changes in documentation requirements for certain E&M services. Reduced reimbursement for new Medicare Part B drugs. These are some of the changes coming to the Medicare Physician Fee Schedule and the Quality Payment Program this year. In the latest ASCO in Action Podcast, ASCO CEO Dr. Clifford A. Hudis discusses the changes made to the physician fee schedule and the Quality Payment Program, and what this may mean for your oncology practice.
The American Society of Clinical Oncology (ASCO) today published standards on the safe handling of hazardous drugs in the Journal of Clinical Oncology. ASCO’s standards largely endorse best practices issued by other stakeholder groups for safely handling hazardous drugs but offer alternatives in several key areas where more research is needed to identify evidence-based safety measures.
As part of the Trump Administration’s continuing effort to address the cost of prescription drugs, the Centers for Medicare & Medicaid Services (CMS) recently solicited input on a proposed new pilot program to test mechanisms for reducing drug costs. The International Pricing Index Model (IPI) for Medicare Part B drugs proposes sweeping reforms that would, in part, benchmark some Medicare Part B drug prices against other countries and change how providers get paid for administering drugs to patients.